- Oticon Medical A/S
Cochlear Limited (Cochlear) proposes to acquire the shares and certain assets of Oticon Medical A/S (Oticon Medical) from Demant A/S.
In Australia, Cochlear and Oticon Medical both supply hearing solutions, specifically cochlear implants and bone conduction solutions.
The ACCC has published a Statement of Issues outlining preliminary competition concerns in relation to the proposed acquisition.
The ACCC invites submissions on its Statement of Issues by close of business on 22 December 2022.
Submissions should be forwarded electronically (preferably in PDF format) to firstname.lastname@example.org with the title “Submission re: Cochlear/Oticon Medical – attention Annabel Garrard / Marisa Kuhlewein”.
Following 22 December 2022, queries regarding the ACCC's review may be addressed to Annabel Garrard / Marisa Kuhlewein at email@example.com
For more details, please refer to the attached Statement of Issues.
|Cochlear Oticon Medical - Market Inquiries letter ( PDF 236.2 KB )||4 Aug 2022|
Statement of issues
|Cochlear Oticon Medical - Statement of Issues ( PDF 280.67 KB )||1 Dec 2022|
|04/08/2022||ACCC commenced informal review under the Informal Merger Review Process Guidelines.|
|23/08/2022||Closing date for submissions.|
|12/10/2022||ACCC is awaiting information from the parties. Former provisional date for announcement of findings (27 October 2022) is delayed.|
|16/11/2022||ACCC timeline recommenced.|
|01/12/2022||ACCC published a Statement of Issues outlining preliminary competition concerns.|
|22/12/2022||Closing date for submissions relating to Statement of Issues.|
|30/01/2023||Timeline suspended pending receipt of information from the parties. Former provisional date for announcement of ACCC's findings (16 March 2023) is delayed. The ACCC will announce a proposed decision date in due course.|
- Marisa Kuhlewein
- Annabel Garrard